Immupharma Share Discussion Threads

[ny boy] 06/4/2018 07:19

Data lock news could appear at anytime of the trading day, doesn’t have to be at 7am

[metis20] 06/4/2018 07:19

Dr B

"I’ve never heard of a “disclosure effect” in a clinical trial (must also admit I’ve not searched for it either) so I took the results at face value."

Extraordinary how behind the curve you were until you read post 23323!

[englishlongbow] 06/4/2018 07:18

On track for greatness.

[gisjob2] 06/4/2018 07:17

I'll be surprised if we get an RNS, the last one told us what we needed to know.

[growthinvestor2001] 06/4/2018 07:15

Would we get a database lock RNS intraday if it is indeed locked today or are they just not going to issue one?

The guessing continues...arghhh!

[goodbloke1] 06/4/2018 07:11

Dr Biotech.Can I ask if you hold any stock or if you want to buy in cheaper?

[dr biotech] 06/4/2018 07:03

I’ve never heard of a “disclosure effect” in a clinical trial (must also admit I’ve not searched for it either) so I took the results at face value.

I could understand that if you found out your were in the trial group that it may give you a boost, but I don’t understand how finding out you were in a placebo group would do the same thing. More likely everyone was told that the overall group was responding without being told individually which group they were in. Either way it’s a concern showing how much the response is in the mind rather than the body. But this is already well established, given the high placebo response (and shows that even the SRI may not be the best way to measure the effectiveness)

It is a valid question to ask how many lupus sufferers will fall in the ITT group.in many cases the symptoms can be mild or treated adequately with low cost steroids etc. The FDA are not going to allow it to be used on a group where there is no clincial benefit.

[mitch101] 05/4/2018 23:24

BA's understudy...DTD
Be aware of the Phorid fly. They don't understand the intricacies of medical statistic. Help yourself by going to Granny or trading OTC Oink. Result could be the same.

[stanman] 05/4/2018 23:16

Also, don't forget that in the Lupuzor P2b study, an interim analysis was done and the results had to be disclosed in accordance with LSE rules. This confounded the ITT Group 24 wk results (the authors claim) and this is discussed in some detail in the discussion section of the report. It was felt that this affected both the SLEDAI and SRI responses observed (quote -"the disclosure effect was huge"). All rather confusing then. But one must be reassured up to a point by Sylviane Muller's comments subsequent to the P2b report, and by the ready acceptance by the FDA of the P3 study with the special allowances they granted.

[pretax2] 05/4/2018 23:14

Respects to you Bullet Ant. Hope we all get what we want...

[dubble trubble doubled] 05/4/2018 23:03

Hope everyone titties and goolies do not get thrashed tomorrow. I done what BA did, open a demo account and started trading his way. You can bet a million squids and never lose any pennies.

[l0ngterm] 05/4/2018 23:02

Thanks for replying. Overall though you have to take the disclosure into consideration, and the follow up assessment as well.

[dr biotech] 05/4/2018 22:59

From the BMJ paper the 12 week score was somewhat better than the 24 weeks score (in terms of benefit vs placebo). The absolute response was higher in the 24 week group - but so was the placebo response. So you can interpret it either way.

It’s just important to measure like for like vs Benlysta, not sledai vs SRI etc.

[l0ngterm] 05/4/2018 22:48

Yeah well I have been round this one once or twice personally. Hence the measurement question and stats query Mitch.

[ashehzi] 05/4/2018 22:40

Which outcome measures in SLE clinical trials best reflect medical judgment?

Key messages
Shortfalls of SRI and BICLA may be due to BICLA requiring only partial improvement but in all organs versus SRI requiring full improvement in some manifestations and not necessarily in all organs.

BICLA may be less sensitive than SRI in determining clinically significant improvement, particularly in SLE patients with multiple organs involved at baseline.

Each instrument could likely be an optimal primary endpoint depending on the population under study and the design of a given clinical trial.

Ps. Based on the success of the BLISS programme, SRI is currently being used in a number of clinical trials for SLE. Nonetheless, the treatment effect achieved by adding belimumab to standard of care using the original SRI (four-point drop in SLEDAI) was at best modest, and it remains unclear whether this is the optimal discriminatory endpoint.

[mitch101] 05/4/2018 22:39

Yeah.....I wish ........... exclusive to informed posts. Isn't that the idea?

[l0ngterm] 05/4/2018 22:29

Is this an exclusive club?

[dr biotech] 05/4/2018 22:18

Sorry mitch I'm not sure on that one.

I've got interested in clinical trials having had so many bio shares that crashed and burned on poor results have had earlier trials hyped - hence my general cynicism. One of the many things that have been overhyped on here is the P2 results, pretty much every ramp has just quoted the less important (but more impressive result) Sledai vs the much more important SRI. Its the SRI score that has to beat (or be close to Benlysta). Obviously less side effects is a bonus.

I'm not saying its going to fail - the SLEDAI is impressive - and 10 years ago I'd have had a lot of these. Fingers burned too many times.

Good luck all, I'm always watching the 7am news..

[mitch101] 05/4/2018 21:50

Dr Bio
Do you have any thoughts on whether the follow on trial may have been instigated by your comments regarding the difference between SLEDAI type results to that of SRI type results?
I have no understanding whatsoever of bio trials but I am beginning to!! So thanks to those few who have posted informative bio/medical stuff.

[bullet ant] 05/4/2018 21:49

Gran is not stoopid to buy anything on OTC and doubt she would waste 0.1 picosec of her time on H to zero comments.


Off to watch Walking Braindead episode. I had enuff of listening to advfn Braindeads today; my first day out of rehab.


Good evening Y'All
BA
Stealing is Good

[mitch101] 05/4/2018 21:32

BA - Better check yer Gran isn't taking H to Zero's comments serious and doing a bit on the side.

[bullet ant] 05/4/2018 21:15

Good evening Mr Mitch

Thank you for lecturing H to Zero about OTC pink Sheets. Hope you do not mind me saying, that you may have assumed that the genuine investors understand what OTC stands for.

I do not think genuine investors know OTC means Over The Counter and what it entails.

Let me give a simplistic analogy to my biutiful emates.

For example going to Londonistan airport Heathrow buying/exchanging FX with Thomas crook at 10% marked up or marked down to spot price, is buying/selling over the counter.

In essence only MUGS buy/sell FX over the counter, or buy anything over the grey market, e.g including shares or drugs. It's a really a bad idea buying/selling via OTC. For drugs, one could be selling to the boys in blues, a very very very bad move.


I needed Blitz chess today to make my neurons to release a massive dose of dopamine as I need to keep up with champs like tops tips & Co; these guys know their sheik.



BA
Stealing is good.

[l0ngterm] 05/4/2018 20:58

Was that the 12 weeks resuults, not the 24 weeks? And excludes the follow on?

[mitch101] 05/4/2018 20:38

H to Zero
OTC Oink sheets are not traded on any exchange. Trades are between individuals - x3 today and they may have been all buys and no sells. Try selling them when you need/want to!!!!
Why spout the daft trades on here as a qualifying & supportive comment?